Remodeling of Paranasal Sinuses Mucosa Functions in Response to Biofilm-Induced Inflammation
Szczepan Kaliniak,Krzysztof Fiedoruk,Jakub Spałek,Ewelina Piktel,Bonita Durnaś,Stanisław Góźdź,Robert Bucki,Sławomir Okła
DOI: https://doi.org/10.2147/jir.s443420
IF: 4.5
2024-02-27
Journal of Inflammation Research
Abstract:Szczepan Kaliniak, 1 Krzysztof Fiedoruk, 2 Jakub Spa&lstrokek, 1, 3 Ewelina Piktel, 2 Bonita Durna&sacute, 1, 3 Stanis&lstrokaw Gó&zacuted&zacute, 1, 3 Robert Bucki, 2, 3 S&lstrokawomir Ok&lstroka 1, 3 1 Holy-Cross Cancer Center, Kielce, Poland; 2 Department of Medical Microbiology and Nanobiomedical Engineering, Medical University of Bia&lstrokystok, Bia&lstrokystok, Poland; 3 Institute of Medical Science, Collegium Medicum, Jan Kochanowski University of Kielce, Kielce, 25-317, Poland Correspondence: S&lstrokawomir Ok&lstroka, Department of Otolaryngology, Head and Neck Surgery, Holy-Cross Cancer Center, Kielce, 25-734, Poland, Tel/Fax +48 41 367 43 36, Email Rhinosinusitis (RS) is an acute (ARS) or chronic (CRS) inflammatory disease of the nasal and paranasal sinus mucosa. CRS is a heterogeneous condition characterized by distinct inflammatory patterns (endotypes) and phenotypes associated with the presence (CRSwNP) or absence (CRSsNP) of nasal polyps. Mucosal barrier and mucociliary clearance dysfunction, inflammatory cell infiltration, mucus hypersecretion, and tissue remodeling are the hallmarks of CRS. However, the underlying factors, their priority, and the mechanisms of inflammatory responses remain unclear. Several hypotheses have been proposed that link CRS etiology and pathogenesis with host (eg, "immune barrier") and exogenous factors (eg, bacterial/fungal pathogens, dysbiotic microbiota/biofilms, or staphylococcal superantigens). The abnormal interplay between these factors is likely central to the pathophysiology of CRS by triggering compensatory immune responses. Here, we discuss the role of the sinonasal microbiota in CRS and its biofilms in the context of mucosal zinc (Zn) deficiency, serving as a possible unifying link between five host and "bacterial" hypotheses of CRS that lead to sinus mucosa remodeling. To date, no clear correlation between sinonasal microbiota and CRS has been established. However, the predominance of Corynebacteria and Staphylococci and their interspecies relationships likely play a vital role in the formation of the CRS-associated microbiota. Zn-mediated "nutritional immunity", exerted via calprotectin, alongside the dysregulation of Zn-dependent cellular processes, could be a crucial microbiota-shaping factor in CRS. Similar to cystic fibrosis (CF), the role of SPLUNC1-mediated regulation of mucus volume and pH in CRS has been considered. We complement the biofilms' "mechanistic" and "mucin" hypotheses behind CRS pathogenesis with the "structural" one – associated with bacterial "corncob" structures. Finally, microbiota restoration approaches for CRS prevention and treatment are reviewed, including pre- and probiotics, as well as Nasal Microbiota Transplantation (NMT). Keywords: rhinosinusitis, chronic rhinosinusitis, nasal polyps, rhinosinusitis pathophysiology, rhinosinusitis pathophysiology, microbiota, nutritional immunity Rhinosinusitis (RS) is an inflammatory disease of the nasal and paranasal sinuses. According to the European Position Paper on Rhinosinusitis and Nasal Polyps 2020 (EPOS 2020), RS is classified into acute (ARS) or chronic (CRS). 1 The categorizing factors involve (i) the presence and type of symptoms, such as nasal blockage, facial pain, cough, reduction or loss of smell, and (ii) their duration, ie, ≤12 weeks for ARS and ≥12 weeks for CRS. Both types of RS are among the most common health issues worldwide. It is estimated that 6–15% of the general population suffers from ARS, one of the most common diagnoses for antibiotic prescriptions. Similarly, CRS affects 5–12% of the global population, and differences in risk factors such as smoking or environmental irritants may account for some geographical variation. 1–4 The overall prevalence of CRS in the general population in Europe and the United States was estimated to be 10.9% and 11.9%, respectively. 1 Comparable percentages were found in the adult general population of other countries, such as South Korea (8.4%), China (8.0%), and Brazil (5.5%). 4 CRS significantly reduces the health-related quality of life (HRQoL), mainly due to nasal obstruction, rhinorrhea, and olfactory impairments, as well as substantially burdens the health care system, even more costly than asthma or peptic ulcer disease. 1,4–7 The implementation of HRQoL questionnaires demonstrates clinical and predictive treatment efficacy and enhances patient care. The Sino-Nasal Outcome Test-22 (SNOT-22) is the most widely utilized and most suitable questionnaire among those frequently employed in rhinology due to its validity, reliability, and usability. 7 Chron -Abstract Truncated-
immunology